NEWS RELEASES
YEAR
-
CANBRIDGE LIFE SCIENCES SUBMITS INVESTIGATIONAL NEW DRUG APPLICATION FOR CAN017 TRIAL IN ESOPHAGEAL SQUAMOUS CELL CANCER (ESCC) IN CHINA
DEC 21, 2017
-
CANBRIDGE COMPLETES PATIENT ENROLMENT FOR PHASE I CLINICAL TRIAL OF CAN008 IN TREATMENT OF GLIOBLASTOMA MULTIFORME IN TAIWAN
NOV 30, 2017
-
CAN008 INJECTION FOR THE TREATMENT OF GBM CHINA TAIWAN PHASE I DATA RELEASING
NOV 02, 2017
-
JAMES XUE IS APPOINTED TO LEADERSHIP AND DEVELOPMENT COUNCIL MEMBER
SEP 26, 2017
-
CANBRIDGE LIFE SCIENCES APPOINTS CHIEF BUSINESS OFFICER WILL HEAD FIRST US OFFICE
SEP 12, 2017
-
CANBRIDGE CONGRATULATES APOGENIX APG101 RECEIVING EMA “PRIME” DESIGNATION
JUL 26, 2017
-
CANBRIDGE SUBMITS IND APPLICATION FOR CAN008 PhII/III TRIAL IN GBM IN CHINA
JUL 18, 2017
-
JAMES XUE, FOUNDER AND CEO OF CANBRIDGE, PRESENT AT 2017 CHINA GCP CONFERENCE
JUN 08, 2017
-
JAMES XUE, FOUNDER AND CEO OF CANBRIDGE, PRESENT AT 2017 BOSTON CEO CONFERENCE
JUN 01, 2017
-
CANBRIDGE LIFE SCIENCES RAISES $25 MILLION IN SERIES B ROUND LED BY LAPAM CAPITAL
MAY 23, 2017
